Get the Stockscreener App
0.73
0.00%
0.00
Cyclo Therapeutics Inc stock is traded at $0.73, with a volume of 25,360.
It is up +0.00% in the last 24 hours and down -1.51% over the past month.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
See More
Previous Close:
$0.73
Open:
$0.73
24h Volume:
25,360
Relative Volume:
0.54
Market Cap:
$21.24M
Revenue:
$1.13M
Net Income/Loss:
$-20.74M
P/E Ratio:
-0.3883
EPS:
-1.88
Net Cash Flow:
$-18.37M
1W Performance:
-2.67%
1M Performance:
-1.51%
6M Performance:
-51.66%
1Y Performance:
-27.72%
1-Day Range:
$0.7012
$0.74
1-Week Range:
$0.7012
$0.767
52-Week Range:
$0.5946
$2.115
Cyclo Therapeutics Inc Stock (CYTH) Company Profile
Name
Cyclo Therapeutics Inc
Sector
Phone
386-418-8060
Address
6714 NW 16TH STREET, SUITE B, GAINESVILLE
Cyclo Therapeutics Inc Stock (CYTH) Latest News
Kuehn Law Encourages CDE, SMC, COFS, and RFL Investors to Contac - GuruFocus.com
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals - BioCentury
Sonoma Pharmaceuticals (SNOA) Surges Amid Positive Analyst Ratin - GuruFocus.com
What Q3 investment banking trends reveal about the economy - Fortune
Will Cyclo Therapeutics Get A Boost From NPC-1 Trial Data? - RTTNews
Pacira BioSciences Appoints Shawn Cross As Chief Financial Officer - citybiz
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer - The Manila Times
Niemann Pick Disease Drug Type C Treatment Market Industry - openPR
Deal Watch: Lilly Turns To Oblique For Antibody Discovery - Scrip
Alkermes (ALKS) Stock Surges Amid Strong Financial Results - GuruFocus.com
Maxim Group Downgrades Cyclo Therapeutics (CYTH) - MSN
Cyclo Therapeutics faces Nasdaq delisting over non-compliance - Investing.com
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Increased by Handelsbanken Fonder AB - Defense World
Cyclo Therapeutics faces Nasdaq delisting over non-compliance By Investing.com - Investing.com UK
Cyclo Therapeutics secures $3 million in funding from Rafael Holdings By Investing.com - Investing.com South Africa
Cyclo Therapeutics secures $3 million in funding from Rafael Holdings - Investing.com India
Kuehn Law Encourages CDE, SMC, COFS, and RFL Investors to Contact Law Firm - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, SMC, COFS, RFL on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX - AccessWire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FYBR, COFS, RFL on Behalf of Shareholders - Lelezard.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders - AccessWire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMAR, MNTX, RFL on Behalf of Shareholders - The Malaysian Reserve
Kuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to Contact Law Firm - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, GATO, RFL on Behalf of Shareholders - The Malaysian Reserve
Take your (Niemann-) Pick: Intrabio’s Aqneursa wins FDA nod - BioWorld Online
Analyzing SOPHiA GENETICS (NASDAQ:SOPH) & Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Cyclo-oxygenase 2 Inhibitors Clinical Trial Pipeline - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COFS, ARC, NBY, RFL on Behalf of Shareholders - GlobeNewswire
Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm - The Malaysian Reserve
HC Wainwright & Co. Initiates Coverage of Cyclo Therapeutics (CYTH) with Buy Recommendation - MSN
Niemann-Pick Disease Type C Npc Market 2024 Opportunity, - openPR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHEB, ARC, RFL on Behalf of Shareholders - The Malaysian Reserve
2024 remains record-breaker for deal value, M&A values double - BioWorld Online
Cyclo Therapeutics secures $3 million convertible note financing By Investing.com - Investing.com Australia
Biotech Working on 'Functional Cure' for Type 1 Diabetes - Streetwise Reports
Cyclo Therapeutics secures $3 million convertible note financing - Investing.com
CYTH stock touches 52-week low at $0.68 amid market challenges - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARCH, CYTH, VGR on Behalf of Shareholders - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (NasdaqCFB), Arch Resources, Inc. (NYSEARCH), Cyclo Therapeutics, Inc. (NasdaqCYTH), Vector Group Ltd. (NYSE - GlobeNewswire Inc.
Cyclo Therapeutics reports progress in NPC treatment trials - Investing.com India
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1) - StockTitan
Cyclo Therapeutics Inc (CYTH) deserves deeper analysis - US Post News
What is Cyclo Therapeutics Inc (CYTH) Stock Return on Shareholders’ Capital? - SETE News
CYTH stock touches 52-week low at $0.77 amid market challenges - Investing.com
Cyclo Therapeutics Inc Stock (CYTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):